** Shares of drug developer 4D Molecular Therapeutics FDMT.O fall 13.2% to $4.79
** Brokerage BMO Capital downgrades rating to "market perform" from "outperform;" cuts PT to $15 from $40
** New PT represents a 171.4% upside to the stock's last close
** FDMT is testing its gene therapy, 4D-150, for the treatment of diabetic macular edema $(DME.AU)$, a condition where fluid builds up in the central part of the retina due to damaged blood vessels
** Brokerage says "4D-150 durability in DME appears limited" with only 56% of patients being injection-free at 32 weeks
** Brokerage believes "upcoming 4D-150 readouts are more likely to drive downside than upside" due to lower injection-free rates and safety risks with longer follow-up
** Brokerage notes wAMD/DME competitive landscape is increasingly crowded, which may pressure the FDMT's thesis
** 8 of 11 brokerages rate the stock "buy" or higher, 2 "hold" and 1 "sell;" their median PT is $39 — LSEG
** FDMT fell 73.6% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.